
-
Zymeworks NasdaqGS:ZYME Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Location: 108 Patriot Drive, Middletown, DE, 19709, United States | Website: https://www.zymeworks.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
569.2M
Cash
265.3M
Avg Qtr Burn
-18.94M
Short % of Float
17.28%
Insider Ownership
0.19%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ziihera® (zanidatamab-hrii) Details Cancer, Solid tumor/s, Biliary Tract Cancer | Approved Quarterly sales | |
Zanidatamab + Chemo/trastuzumab Details Breast cancer, Cancer, HER2-expressing cancers | Phase 3 Initiation | |
Zanidatamab zovodotin (ZW49) Details HER2-expressing cancers, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Zanidatamab (HER2) + chemotherapy + tislelizumab Details Cancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma | Phase 2 Update | |
Zanidatamab (HER2) + docetaxel Details Cancer, Breast cancer | Phase 1/2 Data readout | |
ZW171 Details Cancer, Mesothelin-expressing solid tumors | Phase 1 Data readout | |
ZW191 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
ZW251 (GPC3 ADC) Details Cancer | IND Submission | |
ZW220 (NaPi2b ADC) Details Cancer | IND Submission |